Retatrutide
Overview
Retatrutide extends the same GLP-1/GIP approach used by semaglutide and tirzepatide with a third receptor target, glucagon, thought to add an effect on energy expenditure alongside appetite suppression. Early trial data has drawn significant attention for showing a larger average weight reduction than earlier GLP-1-based compounds, though it’s newer and has a shorter track record than either.
Dosing
See the general Dosing Guide for reconstitution and administration basics.
Further Reading
This page is a general summary, not a literature review. For primary research on Retatrutide, the National Library of Medicine's PubMed database is the standard starting point for peer-reviewed studies:
Search PubMed for Retatrutide research →